Clearpoint Neuro Inc
CLPT14.020USD
-0.470-3.24%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
398.56MMarket Cap
LossP/E TTM
More Details of Clearpoint Neuro Inc Company
ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
Clearpoint Neuro Inc Info
Ticker SymbolCLPT
Company nameClearpoint Neuro Inc
IPO dateJul 03, 2019
CEOBurnett (Joseph Michael)
Number of employees115
Security typeOrdinary Share
Fiscal year-endJul 03
Address120 S. Sierra Avenue
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone19499006833
Websitehttps://www.clearpointneuro.com/
Ticker SymbolCLPT
IPO dateJul 03, 2019
CEOBurnett (Joseph Michael)
Company Executives of Clearpoint Neuro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.08K
-4.84%
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
78.87K
+0.71%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+71.68%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.08K
-14.51%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-19.96%
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Ms. B. Kristine (Kris) Johnson
Ms. B. Kristine (Kris) Johnson
Independent Director
Independent Director
--
--
Dr. Linda M. Liau
Dr. Linda M. Liau
Independent Director
Independent Director
--
--
Mr. Jeremy L. Stigall
Mr. Jeremy L. Stigall
Chief Business Officer
Chief Business Officer
--
--
Mr. R. John Fletcher
Mr. R. John Fletcher
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.08K
-4.84%
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
78.87K
+0.71%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+71.68%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.08K
-14.51%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-19.96%
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Products: Functional neurosurgery
3.43M
37.24%
Services: Biologics and drug delivery
2.87M
31.12%
Products: Biologics and drug delivery
1.87M
20.30%
Product Systems and software products
694.00K
7.53%
Services: Capital equipment and other
350.00K
3.80%
By RegionUSD
Name
Revenue
Proportion
United States
9.21M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Products: Functional neurosurgery
3.43M
37.24%
Services: Biologics and drug delivery
2.87M
31.12%
Products: Biologics and drug delivery
1.87M
20.30%
Product Systems and software products
694.00K
7.53%
Services: Capital equipment and other
350.00K
3.80%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.47%
The Vanguard Group, Inc.
5.03%
Bigger Capital Funds, LP
4.34%
PTC Therapeutics Inc
3.01%
Geode Capital Management, L.L.C.
2.21%
Other
79.94%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.47%
The Vanguard Group, Inc.
5.03%
Bigger Capital Funds, LP
4.34%
PTC Therapeutics Inc
3.01%
Geode Capital Management, L.L.C.
2.21%
Other
79.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.66%
Investment Advisor/Hedge Fund
9.97%
Hedge Fund
7.85%
Individual Investor
4.98%
Corporation
3.01%
Research Firm
1.38%
Bank and Trust
0.10%
Pension Fund
0.03%
Insurance Company
0.02%
Other
52.01%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
238
11.91M
42.82%
-795.00
2025Q3
241
11.91M
44.93%
+805.07K
2025Q2
228
11.11M
37.29%
+1.29M
2025Q1
216
9.82M
36.04%
-268.85K
2024Q4
204
9.20M
33.04%
+1.04M
2024Q3
190
8.15M
32.05%
-235.56K
2024Q2
185
8.39M
33.08%
-454.38K
2024Q1
183
8.85M
30.95%
+359.48K
2023Q4
183
7.82M
35.41%
+717.11K
2023Q3
184
7.11M
35.71%
+336.40K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
1.50M
5.27%
+1.13M
+307.45%
Jun 30, 2025
The Vanguard Group, Inc.
1.48M
5.19%
+191.14K
+14.89%
Jun 30, 2025
Bigger Capital Funds, LP
1.17M
4.1%
+31.67K
+2.79%
Jun 30, 2025
PTC Therapeutics Inc
894.58K
3.15%
--
--
Aug 23, 2024
Geode Capital Management, L.L.C.
624.80K
2.2%
+323.43K
+107.32%
Jun 30, 2025
State Street Investment Management (US)
333.38K
1.17%
+207.53K
+164.91%
Jun 30, 2025
Bigger (Michael)
378.69K
1.33%
--
--
Jun 30, 2025
Brown Advisory
330.90K
1.16%
-191.00
-0.06%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
1.19%
iShares Neuroscience and Healthcare ETF
0.94%
iShares Micro-Cap ETF
0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
Vanguard US Momentum Factor ETF
0.06%
Motley Fool Next Index ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion1.19%
iShares Neuroscience and Healthcare ETF
Proportion0.94%
iShares Micro-Cap ETF
Proportion0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.09%
Vanguard US Momentum Factor ETF
Proportion0.06%
Motley Fool Next Index ETF
Proportion0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.03%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Clearpoint Neuro Inc?
The top five shareholders of Clearpoint Neuro Inc are:
BlackRock Institutional Trust Company, N.A. holds 1.50M shares, accounting for 5.27% of the total shares.
The Vanguard Group, Inc. holds 1.48M shares, accounting for 5.19% of the total shares.
Bigger Capital Funds, LP holds 1.17M shares, accounting for 4.10% of the total shares.
PTC Therapeutics Inc holds 894.58K shares, accounting for 3.15% of the total shares.
Geode Capital Management, L.L.C. holds 624.80K shares, accounting for 2.20% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.50M shares, accounting for 5.27% of the total shares.
The Vanguard Group, Inc. holds 1.48M shares, accounting for 5.19% of the total shares.
Bigger Capital Funds, LP holds 1.17M shares, accounting for 4.10% of the total shares.
PTC Therapeutics Inc holds 894.58K shares, accounting for 3.15% of the total shares.
Geode Capital Management, L.L.C. holds 624.80K shares, accounting for 2.20% of the total shares.
What are the top three shareholder types of Clearpoint Neuro Inc?
The top three shareholder types of Clearpoint Neuro Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Bigger Capital Funds, LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Bigger Capital Funds, LP
How many institutions hold shares of Clearpoint Neuro Inc (CLPT)?
As of 2025Q4, 238 institutions hold shares of Clearpoint Neuro Inc, with a combined market value of approximately 11.91M, accounting for 42.82% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.11%.
What is the biggest source of revenue for Clearpoint Neuro Inc?
In FY2025Q2, the Products: Functional neurosurgery business generated the highest revenue for Clearpoint Neuro Inc, amounting to 3.43M and accounting for 37.24% of total revenue.
